Free Trial

Vir Biotechnology (VIR) Earnings Date, Estimates & Call Transcripts

Vir Biotechnology logo
$9.26
+1.77 (+23.63%)
(As of 11/1/2024 ET)

Vir Biotechnology Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 27Estimated
Actual EPS
(Oct. 31)
-$1.56 Missed By -$0.60
Consensus EPS
(Oct. 31)
-$0.96

Vir Biotechnology posted Q3 2024 earnings on October 31, 2024, reporting an EPS of -$1.56, which missed analysts' consensus estimates of -$0.96 by $0.60. Quarterly revenue fell 9.8% year-over-year to $2.38 million, below analyst estimates of $5.54 million. With a trailing EPS of -$3.92, Vir Biotechnology's earnings are expected to decrease next year, from ($3.26) to ($3.53) per share.

VIR Upcoming Earnings

Vir Biotechnology's next earnings date is estimated for Thursday, February 27, 2025, based off prior year's reporting schedules.

Get Vir Biotechnology Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vir Biotechnology and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

VIR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VIR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Vir Biotechnology Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.99-$0.99-$0.99
Q2 20242-$1.34-$1.12-$1.23
Q3 20242-$1.35-$0.85-$1.10
Q4 20241-$0.71-$0.71-$0.71
FY 20246-$4.39-$3.67-$4.03
Q1 20251-$0.72-$0.72-$0.72
Q2 20251-$0.81-$0.81-$0.81
Q3 20251-$0.89-$0.89-$0.89
Q4 20251-$0.55-$0.55-$0.55
FY 20254($2.97)($2.97)($2.97)

Vir Biotechnology Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/27/2025
(Estimated)
------- 
10/31/2024Q3 2024-$0.96-$1.56 -$0.60-$1.56$5.54M$2.38M      
8/1/2024Q2 2024-$0.89-$1.02 -$0.13-$1.02$7.53M$3.08M        
5/2/2024Q1 2024-$0.99-$0.48+$0.51-$0.48$11.71M$56.38M        
2/22/2024Q4 2023-$1.14-$0.86+$0.28-$0.86$11.18M$16.80M        
11/2/2023Q3 2023-$1.21-$1.22 -$0.01-$1.22$12.57M$2.64M    
8/3/2023Q2 2023-$1.21-$1.45 -$0.24-$1.45$22.39M$3.80M      
5/4/2023Q1 2023-$0.86-$1.06 -$0.20-$1.06$50.10M$63.00M  
2/23/2023Q4 2022-$0.04-$0.76 -$0.72-$0.76$134.24M$49.40M
11/3/2022Q3 2022$0.01$1.30+$1.29$1.30$153.79M$374.56M

Vir Biotechnology Earnings - Frequently Asked Questions

Vir Biotechnology has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates. Learn more on VIR's earnings history.

In the previous quarter, Vir Biotechnology (NASDAQ:VIR) missed the analysts' consensus estimate of ($0.96) by $0.60 with a reported earnings per share (EPS) of ($1.56). Learn more on analysts' earnings estimate vs. VIR's actual earnings.

The conference call for Vir Biotechnology's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Vir Biotechnology's latest earnings report can be read online.
Read Transcript

Vir Biotechnology (NASDAQ:VIR) has a recorded annual revenue of $86.18 million.

Vir Biotechnology (NASDAQ:VIR) has a recorded net income of -$615.06 million. VIR has generated -$3.58 earnings per share over the last four quarters.

Vir Biotechnology's earnings are expected to decrease from ($3.26) per share to ($3.53) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:VIR) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners